{
    "id": 22554,
    "fullName": "ABL1 M237V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 M237V does not lie within any known functional domains of the Abl1 protein (UniProt.org). M237V has been identified in the scientific literature (PMID: 26603839, PMID: 16527898, PMID: 20595523), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 12745,
                    "pubMedId": 16527898,
                    "title": "BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16527898"
                },
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                },
                {
                    "id": 15079,
                    "pubMedId": 20595523,
                    "title": "Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20595523"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "M237V",
    "createDate": "05/15/2016",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 119198,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130862922A>G",
        "cDna": "c.709A>G",
        "protein": "p.M237V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8000,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 T315I (65%), and T315I/M237V (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23174,
                "profileName": "BCR - ABL1 ABL1 M237V ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23173,
            "profileName": "ABL1 M237V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23174,
            "profileName": "BCR - ABL1 ABL1 M237V ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119198,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130862922A>G",
            "cDna": "c.709A>G",
            "protein": "p.M237V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}